What is William Blair's Estimate for PTCT Q3 Earnings?

Key Points

• William Blair forecasts PTC Therapeutics to report a Q3 2025 earnings per share of ($1.51), while the consensus estimate for the full year is ($4.52) per share.
• Multiple analysts have recently adjusted their price targets for PTC Therapeutics, with Wells Fargo raising it to $78.00 and Royal Bank of Canada to $58.00, reflecting positive outlooks.
• PTC Therapeutics reported $10.04 earnings per share last quarter, significantly exceeding expectations of $0.85, alongside a revenue of $1.18 billion.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Stock analysts at William Blair issued their Q3 2025 earnings per share estimates for PTC Therapeutics in a research report issued to clients and investors on Tuesday, July 29th. William Blair analyst S. Corwin anticipates that the biopharmaceutical company will post earnings per share of ($1.51) for the quarter. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share. William Blair also issued estimates for PTC Therapeutics' Q4 2025 earnings at ($1.25) EPS, Q1 2026 earnings at ($0.70) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($2.01) EPS.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share for the quarter, beating the consensus estimate of $0.85 by $9.19. The business had revenue of $1.18 billion during the quarter, compared to analysts' expectations of $437.16 million. PTC Therapeutics had a negative return on equity of 78.56% and a net margin of 33.56%. The firm's revenue for the quarter was down 9.6% compared to the same quarter last year. During the same quarter last year, the business posted ($1.20) EPS.

A number of other equities analysts have also recently issued reports on PTCT. Truist Financial boosted their price objective on PTC Therapeutics from $80.00 to $86.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Wall Street Zen downgraded PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 16th. Bank of America upped their target price on PTC Therapeutics from $68.00 to $84.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. JPMorgan Chase & Co. lowered their target price on PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Finally, Barclays upped their price target on PTC Therapeutics from $42.00 to $46.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 29th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, PTC Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $69.38.

PTC Therapeutics Price Performance

Shares of PTC Therapeutics stock traded up $0.02 on Thursday, reaching $52.13. The company had a trading volume of 1,020,621 shares, compared to its average volume of 1,123,253. The firm has a market cap of $4.13 billion, a price-to-earnings ratio of 8.01 and a beta of 0.54. The firm's 50-day moving average price is $49.21 and its two-hundred day moving average price is $48.75. PTC Therapeutics has a 1 year low of $29.01 and a 1 year high of $58.38.

Institutional Investors Weigh In On PTC Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of PTC Therapeutics by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 9,178,822 shares of the biopharmaceutical company's stock worth $414,332,000 after purchasing an additional 53,688 shares during the period. Wellington Management Group LLP increased its holdings in PTC Therapeutics by 13.2% in the 1st quarter. Wellington Management Group LLP now owns 5,419,172 shares of the biopharmaceutical company's stock valued at $276,161,000 after purchasing an additional 632,049 shares in the last quarter. Toronto Dominion Bank acquired a new stake in PTC Therapeutics in the 4th quarter valued at $148,363,000. Janus Henderson Group PLC increased its holdings in PTC Therapeutics by 24.4% in the 4th quarter. Janus Henderson Group PLC now owns 2,325,915 shares of the biopharmaceutical company's stock valued at $105,015,000 after purchasing an additional 455,698 shares in the last quarter. Finally, Driehaus Capital Management LLC lifted its stake in shares of PTC Therapeutics by 45.3% in the first quarter. Driehaus Capital Management LLC now owns 1,512,645 shares of the biopharmaceutical company's stock worth $77,084,000 after acquiring an additional 471,586 shares in the last quarter.

Insider Transactions at PTC Therapeutics

In related news, VP Mark Elliott Boulding sold 883 shares of the business's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $46.02, for a total value of $40,635.66. Following the transaction, the vice president owned 103,901 shares in the company, valued at $4,781,524.02. The trade was a 0.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Pierre Gravier sold 2,516 shares of the business's stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $49.46, for a total value of $124,441.36. Following the completion of the transaction, the chief financial officer owned 71,920 shares in the company, valued at $3,557,163.20. This trade represents a 3.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,328 shares of company stock worth $254,158 in the last quarter. Insiders own 5.50% of the company's stock.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.